# 18F-MFBG Imaging for Evaluation of Neuroendocrine Malignancies

> **NCT02348749** · PHASE1,PHASE2 · COMPLETED · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 48 (actual)

## Conditions studied

- Neuroendocrine Tumors

## Interventions

- **RADIATION:** 18F-MFBG (meta-fluoro benzylguanidine)
- **DEVICE:** Positron emission tomography (PET) imaging
- **OTHER:** Blood draws

## Key facts

- **NCT ID:** NCT02348749
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-01
- **Primary completion:** 2025-03-17
- **Final completion:** 2025-03-17
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2025-03-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02348749

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02348749, "18F-MFBG Imaging for Evaluation of Neuroendocrine Malignancies". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT02348749. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*